Bhm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD
We believe that powerful treatments like CJC 1295 and Ipamorelin should be part of a bigger pictureyour overall health and wellness
Retatrutide Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, offering a broader metabolic response compared to tirzepatide
Zinc acts as a cofactor, stabilizing thymulin's structure and ensuring its proper function in immune regulation
However, retatrutide is a first-in-class triple agonist (targeting GIP, GLP-1, and glucagon receptors simultaneously), which may lead to more cautious FDA review compared to drugs with established mechanisms